-
Enliven Therapeutics, Inc NasdaqGS:ELVN Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a CNS penetrant and irreversible HER2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 driven cancers and solid tumors. The company is headquartered in Boulder, Colorado.
Location: 6200 Lookout Road, Boulder, CO, 80301, United States | Website: https://www.enliventherapeutics.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
581.6M
Cash
289.6M
Avg Qtr Burn
-18.49M
Short % of Float
24.60%
Insider Ownership
5.56%
Institutional Own.
-
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
ELVN-002 monotherapy Details Cancer, Solid tumor/s, Non-small cell lung carcinoma | Phase 1 Data readout | |
ELVN-001 Details Chronic myelomonocytic leukemia, Blood cancer, Cancer | Phase 1 Update | |
ELVN-002 w/ trastuzumab +/- chemotherapeutic agents Details Cancer, Metastatic breast cancer, Metastatic colorectal cancer | Phase 1a Data readout |